12:00 AM
 | 
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Rapiscan regadenoson regulatory update

The German Institute for Quality and Efficiency in Health Care (IQWiG) said Rapiscan regadenoson from Rapidscan Pharma Solutions Inc. (Los Altos, Calif.) provides "no additional benefit" over adenosine for use as a pharmacological stress agent in myocardial perfusion imaging (MPI) in adults unable to undergo adequate exercise stress to diagnose coronary artery disease...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >